Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP earnings Wednesday of $0.69 per diluted share, up from $0.60 a year earlier.

Analysts polled by Capital IQ expected $0.66.

Net revenue for the quarter ended Sept. 30 was $4.33 billion, up from $3.85 billion a year earlier.

Analysts polled by Capital IQ expected $4.13 billion.

The company said it now expects full-year 2024 non-GAAP diluted EPS of $2.40 to $2.50, compared with $2.30 to $2.50 previously. Analysts surveyed by Capital IQ expect $2.45.

Revenue for the year is now expected to be from $16.1 billion to $16.5 billion, from a prior guidance of $16 billion to $16.4 billion. Analysts surveyed by Capital IQ expect $16.26 billion.

Shares of the company were up 3.9% in recent Wednesday premarket activity.

Price: 19.50, Change: +0.73, Percent Change: +3.89